RYZUMVI Drug Patent Profile

Which patents cover Ryzumvi, and when can generic versions of Ryzumvi launch?

Ryzumvi is a drug marketed by Famygen Life Sci and is included in one NDA. There are six patents protecting this drug.

This drug has twenty-three patent family members in sixteen countries.

The generic ingredient in RYZUMVI is phentolamine mesylate. There are four drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the phentolamine mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ryzumvi

A generic version of RYZUMVI was approved as phentolamine mesylate by HIKMA on March 11^th, 1998.

Summary for RYZUMVI

International Patents:	23
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Formulation / Manufacturing:	see details
What excipients (inactive ingredients) are in RYZUMVI?	RYZUMVI excipients list
DailyMed Link:	RYZUMVI at DailyMed

Pharmacology for RYZUMVI

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for RYZUMVI

C04AB	Imidazoline derivatives
C04A	PERIPHERAL VASODILATORS
C04	PERIPHERAL VASODILATORS
C	Cardiovascular system

V03AB	Antidotes
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

US Patents and Regulatory Information for RYZUMVI

RYZUMVI is protected by six US patents and one FDA Regulatory Exclusivity.

Patents protecting RYZUMVI

FDA Regulatory Exclusivity protecting RYZUMVI

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes			Y
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes			Y
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes			Y
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes			Y
Famygen Life Sci	RYZUMVI	phentolamine mesylate	SOLUTION;OPHTHALMIC	217064-001	Sep 25, 2023		RX	Yes	Yes			Y

International Patents for RYZUMVI

See the table below for patents covering RYZUMVI around the world.

Country	Patent Number	Title	Estimated Expiration
Mexico	2021004708	METODOS Y COMPOSICIONES PARA TRATAMIENTO DE PRESBICIA, MIDRIASIS Y OTROS TRASTORNOS OCULARES. (METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS.)
Japan	2016506966	フェントラミンの水性点眼液およびそれらの医学的用途
Spain	2762153
Australia	2018200566	AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF
Canada	2899339	SOLUTIONS OPHTALMIQUES AQUEUSES DE PHENTOLAMINE ET UTILISATIONS MEDICALES ASSOCIEES (AQUEOUS OPHTHALMIC SOLUTIONS OF PHENTOLAMINE AND MEDICAL USES THEREOF)
Singapore	11202104094Y	METHODS AND COMPOSITIONS FOR TREATMENT OF PRESBYOPIA, MYDRIASIS, AND OTHER OCULAR DISORDERS
Israel	282624	שיטות והרכבים לטיפול בזוקן ראיה, מידריאזיס והפרעות אחרות של העיניים (Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders)